Product logins

Find logins to all Clarivate products below.

home   •  Research Reports  •  DRG Market Assessment Reports

Malignant Melanoma | Emerging Therapies | Keytruda (pembrolizumab) | US | Wave 3 | 2015

Login to access report north_east
Contact sales account_box

LaunchTrends: Keytruda Wave 3 (US) is the third in a series of syndicated reports designed to track physician perception, uptake, and competitive environment regarding the malignant melanoma drug Keytruda (Merck & Co.’s pembrolizumab).

LaunchTrends: Keytruda measures the impact of this novel agent on the unresectable or metastatic malignant melanoma therapy market following launch, based on a blend of quantitative and qualitative primary research with US medical oncologists. The report evaluates physicians’ current awareness and perception of Keytruda relative to other currently available therapies for unresectable or metastatic malignant melanoma, current and anticipated use of Keytruda, and promotional activity for Keytruda. LaunchTrends: Keytruda Wave 2 and 3 also assess surveyed medical oncologists’ perceptions of Opdivo (Bristol-Myers Squibb’s nivolumab), and Opdivo in combination with Yervoy (Bristol-Myers Squibb’s ipilimumab) following their approval for the treatment of malignant melanoma in December 2014 and October 2015, respectively. Surveyed and interviewed medical oncologists were questioned on their awareness, perception, and prescription of Opdivo with respect to treating malignant melanoma patients.

Questions Answered:

  • What is the awareness of and familiarity with Keytruda and Opdivo among medical oncologists?
  • What are the perceived clinical advantages and disadvantages of Keytruda compared with other marketed agents (including Opdivo) used for treating unresectable or metastatic malignant melanoma?
  •  To what extent are Keytruda, Opdivo, and Opdivo/Yervoy currently being used by surveyed medical oncologists? Where do they fit in the treatment algorithm? What reasons do nonprescribers give for not having prescribed Keytruda?
  •  What promotional messages are being employed by Merck & Co. for Keytruda?

Scope: 

Markets covered: United States.

Primary research: 76 medical oncologists; qualitative interviews with 10 respondents.

Indication coverage: unresectable or metastatic malignant melanoma.

Contact sales account_box
Login to access report north_east

Related Market Assessment Reports

Report
Multiple Myeloma – Current Treatment – Treatment Sequencing – Multiple Myeloma (US)
Key benefits and usesPinpoint current drug positioning and uptake in one snapshot to facilitate forecasting.Drill down into physicians’ treatment sequences and understand who to position against…
north_east
Report
Epilepsy – Unmet Need – Unmet Need – Dravet Syndrome (US/EU)
Dravet syndrome (DS) is a rare, severe, pediatric-onset genetic epileptic encephalopathy that typically emerges within the first year of life and is marked by developmental delays and multiple…
north_east
Report
Alzheimer’s Disease – Unmet Need – Unmet Need – Agitation in Alzheimer’s Disease (US/EU)
Agitation affects most Alzheimer’s disease (AD) patients and comprises a constellation of disruptive symptoms for patients and their families, which may contribute to nursing home placement…
north_east
Report
Breast Cancer – Unmet Need – Unmet Need – Metastatic HR-Positive / HER2-Negative Breast Cancer (US/EU)
The landscape of advanced HR-positive / HER2-negative breast cancer treatment is continually evolving. CDK4/6 inhibitors (Pfizer’s Ibrance, Novartis’s Kisqali, and Eli Lilly’s Verzenio)…
north_east
Report
Hepatitis B Virus – Geographic Focus: China – China In-Depth – Hepatitis B Virus
HBV is a major public health burden in China, with chronically infected individuals at a significantly increased risk of developing hepatic cirrhosis and hepatocellular carcinoma. Current treatment…
north_east

Follow us

Contact us

Sales enquiries north_east
Customer service north_east
Support north_east